29 C
Vientiane
Monday, October 27, 2025
spot_img
Home Blog Page 36

SynbioTech Brings Taiwan’s Biotech Excellence to the Global Stage with TWK10® for Muscle Performance and Healthy Aging

LAS VEGAS, Oct. 23, 2025 /PRNewswire/ — In a field where scientific validation defines credibility, Synbio Tech Inc., a biotechnology company from Taiwan, is gaining international recognition with its proprietary probiotic Lactiplantibacillus plantarum TWK10®. The clinically proven strain, which will be featured at SupplySide Global 2025 from October 27–30 (Booth #6253F), has shown measurable benefits on muscle strength, endurance, and balance—offering a new microbiome-based approach to healthy aging and active living.

SynbioTech will feature its flagship probiotic TWK10® at SupplySide Global 2025, highlighting its clinically proven role in muscle health and active aging.
SynbioTech will feature its flagship probiotic TWK10® at SupplySide Global 2025, highlighting its clinically proven role in muscle health and active aging.

Backed by over a decade of research, TWK10® has been evaluated in peer-reviewed human clinical studies, demonstrating proven benefits in both active individuals and older adults. Clinical findings show that TWK10 boosts endurance performance by 20-40% and increases muscle mass by 0.5-1 kg, while improving overall strength, recovery, and mobility across life stages. One of these landmark studies was recognized by Wiley as a “Top Cited Article,” underscoring TWK10®’s scientific impact and its growing influence in gut–muscle axis research.

TWK10® has earned strong credibility and recognition across global regulatory frameworks, including U.S. GRAS Self-Affirmed status, Korea’s Health Functional Food approval, Taiwan’s Health Food certification with an anti-fatigue claim, Malaysia’s MAL registration, and Thailand’s probiotic listing.

The recent Japan FFC authorization marks another milestone, positioning TWK10® among the most clinically and regulatorily validated probiotics for muscle health worldwide. Together with a growing portfolio of real-world data, these achievements reinforce SynbioTech’s reputation as a science-driven innovator delivering microbiome-based health solutions through probiotics and postbiotics.

“For SynbioTech, it’s more than a product story—it’s about proving how microbiome science can truly enhance daily life,” said Chuan-Hsien Yang, Chief Operating Officer at SynbioTech. “TWK10® is the result of years of research that bridge traditional fermentation knowledge from Taiwan with modern clinical science.”

SynbioTech continues to expand its global partnerships and research collaborations, reflecting a broader vision to connect Asian innovation with global health markets and empower people to live healthier through microbiome science.

About Synbio Tech Inc.
Founded in 2000, Synbio Tech is a global biotechnology company specializing in probiotics, postbiotics, and microbiome-based health solutions. With over 25 years of R&D experience and a fully integrated CDMO platform, the company partners with more than 600 brands across 35 countries to deliver “From Strain to Solution” innovations that change lives with probiotics.
www.synbiotech.com

Retro Stage Unveils 2025 Vintage “Happy Halloween” Collection

MONTEREY, Calif., Oct. 23, 2025 /PRNewswire/ — Vintage-inspired clothing brand Retro Stage is gearing up for the fast-approaching freaky festivities with the reveal of their 2025 Halloween collection. The Happy Halloween line is filled to the brim with frighteningly fabulous looks, featuring pieces inspired by spooky motifs, beloved fictional characters, and of course, classic creatures.

A Nostalgic Vision of Halloween

retro-stage-vintage-halloween-collection
retro-stage-vintage-halloween-collection

Retro Stage is eager to once again share their nostalgic vision of Halloween with their audience, with many hand-picked seasonal favorites returning in addition to the dozens of brand-new designs making their debut. Perfectly blending vintage cuts and aesthetics with delightfully creepy subject matter, this collection’s offerings span all the way from the elegant 1930s to the unconventional 1980s, meaning fans of all decades can be sure to find something to their tastes.

What to Expect from the Vintage Halloween Collection

Retro Stage provided the following sneak peek of what customers can expect to see in this new and exciting collection:

Festive Favorites

From vibrant purple bats to cozy sweaters of orange and black, this collection features everything a Halloween fan needs to rep their spooky spirit all month long. Customers can express themselves with blood-spattered dresses, skull-patterned lace, fun monochrome looks, and so much more.

Punk & Goth Picks

Halloween is a time for the darker side of fashion to take the spotlight, and that’s where the punks and goths come in. Both veterans and newcomers in these iconic subcultures are welcome to shop this collection’s abundance of lacy corsets, leather, silver studs, and blood-red velvet to assemble the perfect retro stage Halloween outfits.

Movie & TV Characters

Fans of Halloween classics like Beetlejuice and The Nightmare Before Christmas are in for a treat, because this collection has all the vintage-inspired costume pieces they could ask for. What’s more, there’s plenty of other pop culture couture in store, including designs inspired by Disney princesses, the beloved Addams family, the Sanderson sisters, the Mystery Gang, and even classic horror films like Carrie — with a haunting Carrie costume that’s both elegant and terrifying.

The brand emphasized their excitement to share both new and returning creations with fans this year in the hopes of making every customer’s Halloween that much more special.

“Halloween and vintage fashion have always gone hand in hand,” said CEO when asked about the collection. “All the most classic horror and monster movies came out at the same time that the most iconic retro aesthetics were first hitting the scene. We had costumers incorporating what was popular at the time into their designs, and when those designs debuted to audiences, they went on to inspire future fashion trends and sort of set the tone for what we still see in scary movies and modern Halloween costumes.” He went on to note that while plenty of costume stores stock vintage-inspired pieces, Retro Stage’s high-quality vintage Halloween costumes & dresses can be reworn and even incorporated into other outfits once Halloween is over, firmly setting the brand apart from the average retailer.

Those interested in celebrating a vintage-style holiday are invited to check out the Happy Halloween collection on the Retro Stage website and pick out their favorite spooky seasonal pieces before time runs out to shop. Customers can also explore the Halloween Sale page for heavily discounted offerings guaranteed to ship in 8 days or less.

About Retro Stage

Retro Stage is a popular vintage fashion brand featuring classic clothing and accessories inspired by 20th-century aesthetics. As a vintage style pioneer, Retro Stage is more than a brand; it’s a way of life, helping every customer explore the history of fashion through chic and glamorous retro style. “Beauty never fades,” said the Retro Stage team. “All we want to do is encourage women to build a better life for themselves and confidently embrace their natural allure.”

ROYAL CARIBBEAN REVEALS SUMMER 2027 ADVENTURES TO ALASKA

Vacationers are in for an action-packed lineup from Anthem of the Seas and its first-ever Cruisetour experiences to more ways to explore on Quantum, Serenade and Voyager of the Seas

MIAMI, Oct. 22, 2025 /PRNewswire/ — Calling all adventure-seekers: Royal Caribbean has revealed its lineup of summer 2027 getaways for travelers to experience the wonders of Alaska. Vacationers can secure their front-row seats to The Last Frontier on weeklong voyages on Anthem, Quantum, Serenade and Voyager of the Seas. The boldest adventures on land and at sea are on deck with 7-night adventures from Seattle; Seward, Alaska; and Vancouver, British Columbia in Canada, along with ways to take exploration to the next level with multi-night Cruisetour experiences on land. The 2027 Alaska vacations are now open to book on Royal Caribbean’s website for Crown & Anchor Society loyalty members, ahead of the official opening on Thursday, Oct. 23.

Serenade of the Seas features ocean-facing glass elevators and floor-to-ceiling windows, delivering to vacationers breathtaking sights of every destination. The Radiance Class vacation also touts experiences for guests of all ages, from rock climbing to poolside movie nights under the stars, to favorite restaurants such as Chops Grille, Giovanni’s Table and Izumi.
Serenade of the Seas features ocean-facing glass elevators and floor-to-ceiling windows, delivering to vacationers breathtaking sights of every destination. The Radiance Class vacation also touts experiences for guests of all ages, from rock climbing to poolside movie nights under the stars, to favorite restaurants such as Chops Grille, Giovanni’s Table and Izumi.

From incredible landscapes to breathtaking wildlife, opportunities for exploration include whale watching in Sitka, Alaska, meeting professional dog sledders and their dog teams at Mendenhall Glacier near Juneau, Alaska, sky high views of Alaska’s wilderness on helicopter tours and more. The memorable experiences continue on board with a variety of ways to thrill, chill, dine and be entertained for all ages. With the all-glass North Star observation capsule, rock-climbing walls, SeaPlex – featuring bumper cars, a sports court and roller-skating – and more, vacationers of all ages have ways to adventure at every corner.

Alaska Summer 2027 Highlights 

  • Anthem of the Seas – From Vancouver and Seward
    Vacationers on Anthem can explore the state’s beauty on 7-night vacations from Seward and Vancouver to picturesque spots like Skagway and Ketchikan and through Hubbard Glacier. Plus, for the first time on Anthem, travelers can dial up the action before or after their adventure with a lineup of immersive overnight Cruisetour experiences on land. The expertly guided multi-night land expeditions span from exploring the must-see Denali National Park to journeys in luxury glass dome rail cars that put the sights of Alaska on full display. The memory making continues on Anthem with activities like the North Star all-glass observation capsule and the largest indoor activity space at sea with SeaPlex, along with flavors for every palate like Mediterranean-inspired dishes at Solarium Bistro, American classics at Johnny Rockets and more.
  • Quantum of the Seas – From Seattle
    After a summer Down Under in Australia, Quantum of the Seas will sail 7-night vacations from Seattle to incredible landscapes across Sitka, Juneau and Skagway, where travelers can kayak in pristine waters and spot sea otters and other wildlife along the shore. More adventures await with the fan-favorite FlowRider surf simulator, an outdoor movie screen and laser tag. When it’s time to refuel, there’s a variety of ways to dine, including family-style Tuscan favorites at Jamie’s Italian, premium steaks at Chops Grille and fresh sashimi at Izumi.
  • Serenade of the Seas – From Vancouver
    Vacationers can embark on weeklong explorations through Alaska’s Inside Passage with majestic sights at Sitka, Icy Strait Point and Ketchikan. More activities for the whole family are in store onboard with a rock-climbing wall, poolside movie nights under the stars, live music at Schooner Bar, and flavors from restaurants such as Giovanni’s Table, Chops Grille and Izumi.
  • Voyager of the Seas From Seattle
    Travelers can marvel at the natural beauty of Alaska for seven nights with visits to Juneau, Skagway, and take in the breathtaking views of Endicott Arm and Dawes Glacier. Every kind of vacationer can make memories while on Voyager with an adults-only, indoor-outdoor Solarium for some relaxation time and ice skating, a mini golf course, laser tag and more.

Vacationers can learn more about the upcoming Alaska adventures on Royal Caribbean’s website.

About Royal Caribbean
Royal Caribbean, part of Royal Caribbean Group (NYSE: RCL), has delivered memorable vacations for more than 50 years. The cruise line’s game-changing ships and exclusive destinations revolutionize vacations with innovations and an all-encompassing combination of experiences, from thrills to dining and entertainment, for every type of family and vacationer. Voted “Best Cruise Line Overall” for 22 consecutive years in the Travel Weekly Readers Choice Awards, Royal Caribbean makes memories with adventurers across more than 300 destinations in 80 countries on all seven continents, including the line’s top-rated exclusive destination, Perfect Day at CocoCay in The Bahamas.   

Media can stay up to date by following @RoyalCaribPR on X and visit www.RoyalCaribbeanPressCenter.com. For additional information or to book, vacationers can visit www.RoyalCaribbean.com, call (800) ROYAL-CARIBBEAN or contact their travel advisor.  

 

Largest Milestone Payment Secured: Biokin, a Rising Chinese Pharmaceutical MNC

BEIJING, Oct. 22, 2025 /PRNewswire/ — In October 2025, a partnership between Biokin—a rising star in China’s innovative pharmaceutical sector—and global pharmaceutical leader BMS triggered a $250 million milestone payment. This is believed to be the largest antibody-drug conjugate (ADC) milestone payment among hundreds of out-licensing deals involving Chinese innovative drugs. Notably, the overall transaction had previously set a record for the total value of a single-drug asset license in China.

iza-bren, a potential first-in-class ADC comprised of an EGFR x HER3 bispecific antibody conjugated
iza-bren, a potential first-in-class ADC comprised of an EGFR x HER3 bispecific antibody conjugated

In recent years, China’s dynamic pharmaceutical ecosystem has rapidly emerged as one of the world’s leading sources of novel drug molecules. Such collaborations, however, often come with uncertainties in both China and the U.S. Following the $800 million upfront payment received in early 2024, Biokin’s partnership with BMS has advanced smoothly once again. This progress has prompted skeptics to recognize iza-bren’s blockbuster potential.

The momentum behind the collaboration stems from the continued validation of iza-bren’s efficacy. At the 2025 World Congress on Lung Cancer (WCLC), after Dr. Fang Wenfeng presented domestic clinical data, a physician from the prestigious MD Anderson Cancer Center in the U.S. approached him, expressing hope the drug would launch in the U.S. as soon as possible.

Such a conversation would have been unimaginable in the past. Despite remarkable progress of China’s biopharmaceutical industry over the past decade, nearly all first-in-class new drugs still originate from Western countries. While China has accelerated efforts to bring in overseas innovations, it has also strongly supported domestic pharmaceutical companies and clinical systems in pursuing innovation.

Dr. Fang works at the renowned Sun Yat-sen University Cancer Center (SYSUCC), where his team has conducted clinical research on iza-bren for several years. In a study of 50 patients with locally advanced or metastatic EGFR-mutated NSCLC—who had received first-line treatment with other drugs but no chemotherapy—iza-bren controlled tumor progression for over a year, nearly doubling the duration achieved by the current global standard of care.

More positive data about iza-bren emerged at the 2025 European Society for Medical Oncology (ESMO) Congress in mid-October. For the first time, results from the pivotal Phase III registration trial of this global first-in-class EGFR×HER3 bispecific ADC were reported: the drug achieved a twofold improvement in key efficacy endpoints in third-line or above treatment for nasopharyngeal carcinoma (NPC). The full study results were published in The Lancet, a leading international medical journal.

More than 40 clinical studies of iza-bren are currently underway worldwide, including 10 Phase III registration trials in China and 3 key registration studies overseas. Regulators in China and the U.S. have designated some of these studies as “Breakthrough Therapies” to expedite development. The drug is expected to launch first in China in 2026—three years earlier than its planned U.S. launch—marking a milestone moment for China’s innovative pharmaceutical sector.

Growing industry consensus on iza-bren’s blockbuster potential began at the 2023 ASCO Annual Meeting. At the time, Professor Zhang Li from SYSUCC first reported promising efficacy signals of the drug’s Phase I trial.

Iza-bren’s unique bispecific ADC technology and its ability to target two high-value antigens (EGFR and HER3) have endowed it with strong efficacy and broad applicability. This has attracted multinational pharma giants facing looming patent cliffs and eager to expand their ADC portfolios. BMS reached a global co-development and commercialization agreement with Biokin, the developer of iza-bren, at a potential total value of up to $8.4 billion.

Biokin distinguishes itself among China’s biotech companies with its unconventional approach. It transitioned from a generic drug manufacturer, and its founder, Zhu Yi, holds no medical degrees from Europe or the U.S., nor has he worked at multinational pharmaceutical companies. Over a decade ago—when the Chinese government first began mapping out the blueprint for its innovative drug ecosystem—Zhu made a firm decision to go all-in on innovative drug R&D. In 2014, amid a global downturn in drug development, he established a lean scientific team in Seattle, U.S., marking the start of his drug R&D journey. Zhu fully leveraged the strengths of both the Chinese and U.S. biopharmaceutical ecosystems: in the U.S., he accessed resources that support early-stage innovation; in China, the efficient regulatory system, large pool of engineers, and abundant patient resources enabled the rapid translation of innovative ideas into reality.

Zhu negotiated distinctive terms with BMS: beyond the substantial financial offer, he secured overseas R&D and commercialization rights. He firmly believes the latter is essential for Biokin to truly join the ranks of global pharmaceutical companies. The establishment and progress of this ambitious collaboration model have empowered Biokin to send a strong message for China’s biotech industry: to become a multinational company within five years.

Beyond iza-bren, Biokin also announced clinical trial results for T-bren, its second ADC drug in Phase III, at the ESMO Congress. Targeting common cancers such as lung, gastric, and breast cancer, T-bren also showed strong signals of becoming a best-in-class drug. Additionally, China’s CDE recently approved Biokin’s first antibody-radionuclide conjugate (ARC) drug to enter clinical trials.

Biokin’s story has captured the market’s attention. On China’s mainland stock exchanges, its market value has surged 15-fold in just over two years. Now, Hong Kong’s capital market is embracing the company. Amid the hesitation of onlookers, Biokin may well emerge as a global leader in biopharmaceuticals.

Data Zoo Partners with Ping Identity to Power PingOne Verify with Global Authoritative Data

SYDNEY, Oct. 22, 2025 /PRNewswire/ — Data Zoo, the trusted data layer for global identity verification, today announced its partnership with Ping Identity, a leader in securing digital identities for the world’s largest enterprises. The strategic relationship provides authoritative data to PingOne Verify, offering businesses a faster, frictionless, and secure way to verify identities across global markets.

Data Zoo joins a growing list of technology partners developing integrations through the Ping Identity Global Technology Partner Program. Partner solutions built on the Ping Identity Platform help organizations compete in a new digital era where user experience is increasingly important, and security cannot be sacrificed.

“Our partnership with Ping Identity advances digital trust by bringing authoritative data into the PingOne Verify platform,” said Jon Jones, Chief Revenue Officer at Data Zoo. “By continually expanding our global authoritative data network, we enable real-time, trusted insights that increase customer assurance and help PingOne Verify stay ahead of sophisticated identity fraud.”

Ping customers can now enhance identity verification through Data Zoo’s global integration, providing secure access to authoritative data from more than 60 countries. As the trusted data layer for identity verification, Data Zoo continually refines its data sources to meet evolving client needs and embeds privacy and compliance into every layer, helping enterprises accurately verify customers, prevent fraud, and deliver secure onboarding at scale.

“Ping Identity is committed to expanding our technology partner ecosystem to enhance digital customer experiences across the entire user journey,” said Loren Russon, Senior Vice President of Product & Technology at Ping Identity. “Our collaboration with Data Zoo makes it seamless for our customers to add unique and multi-faceted data sets to the Ping Identity Platform, which provides real-time, automated verification for both individuals (KYC) and businesses (KYB). Our partnership and solution offering with Data Zoo is key to Ping Identity’s vision of verified trust.”

About Data Zoo
Data Zoo is the trusted data layer for global identity verification. Our single integration provides businesses with secure access to high-quality, privacy-first data from authoritative sources in over 60 countries, including registries, credit bureaus, telcos, and government databases. Through intelligent sequencing and pre-validation, Data Zoo delivers faster, more accurate verification while reducing costs and complexity. Leading enterprises and identity providers trust our data and expertise to strengthen compliance, prevent fraud, and onboard more customers globally.

Data Zoo Media Contact:
Emma Murphy
Marketing & Communications Director
emma.murphy@datazoo.com 

About Ping Identity
At Ping, we make it possible to trust every digital moment—moments with customers, employees, partners, and non-human identities. Whether you’re securing millions of users, fighting sophisticated fraud, simplifying third-party access, or embracing passwordless experiences and verifiable credentials, establishing trust shouldn’t slow you down. Our enterprise-grade identity platform is built for scale, speed, and flexibility—and works seamlessly with your existing tech stack across cloud, hybrid, and on-prem. We help innovators like you accelerate growth and confidently leverage AI—making life easier for your developers, users, IT teams, and partners. With Ping, all your digital experiences start with trust. Learn more at pingidentity.com.

Ping Identity Media Relations
press@pingidentity.com

The Blood Center in New Orleans modernizes platelet processing with FDA-cleared automation from Terumo Blood and Cell Technologies

— Second U.S. site to deploy the Reveos system, boosting platelet supply and reducing waste

LAKEWOOD, Colo., Oct. 22, 2025 /PRNewswire/ — To help address platelet shortages and streamline blood center operations, The Blood Center in New Orleans has become the second U.S. blood center to implement the Reveos Automated Blood Processing System and the Lumia Software Platform from Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company and global leader in blood management solutions. The move marks a significant step forward in transforming how blood centers process blood in the U.S.

Already used globally in more than 60 countries, Reveos brings a decade of proven performance to the U.S. market. Cleared by the U.S. Food and Drug Administration (FDA) in August 2023, Reveos is the only whole blood automation system available in the U.S. that separates whole blood into platelets, plasma and red blood cells in a single fully automated centrifugation cycle.

This technology enables faster processing, greater efficiency in blood component production compared to manual methods and consistently high product quality — helping blood centers meet growing demand for platelets while improving operational performance.

Why whole blood automation matters

Across the United States, blood centers are facing mounting challenges: platelet shortages, staffing constraints and aging donor populations are straining the system.[1,2] Nearly 98% of the U.S. platelet supply comes from apheresis donations — a process through which platelets are collected directly from a single donor using specialized equipment over a longer session.[3] Until now, apheresis has been the primary collection method to produce platelets in the U.S.

Whole blood-derived platelets (WBDPs) offer a complementary solution. Instead of collecting platelets directly, blood centers collect whole blood and then separate it into its components, including platelets, after donation. Historically, this was done using manual methods that took up to 26 steps and were less efficient and more variable. Automation through Reveos has changed that. Now, WBDPs can be produced consistently and quickly, helping organizations like The Blood Center — which must collect 200 to 250 pints of blood daily to meet regional demand[4] — expand their platelet supply.

“The Blood Center’s adoption of Reveos marks a pivotal moment in the evolution of blood processing in the U.S.,” said Chetan Makam, Senior Vice President and General Manager of Global Blood Solutions at Terumo BCT. “Their commitment to innovation and community impact reflects the very purpose of Reveos, which is to empower blood centers with automation that enhances efficiency, consistency, and responsiveness. We’re proud to support their journey and excited to see the ripple effects this transformation will have across the region.”

A decade in the making

With four devices now in routine use, The Blood Center is realizing its vision of modernized blood processing. The investment helps optimize operational efficiencies, frees up time for staff to do other tasks and enhances the process for platelet production and consistency — helping to benefit donors, hospitals and the broader community.

“This is a milestone moment for our center,” said Mickie Wilson-Martin, Production and Distribution Manager at The Blood Center. “We’ve waited a long time for a solution like this — one that truly modernizes how we manage whole blood. Being among the first in the U.S. to implement Reveos is something we’re incredibly proud of, and it sends a powerful message as we work to attract younger talent. We may be small, but we are mighty, and we’re here for our community.”

From manual to automated: A new era begins

Reveos automates the balancing, centrifuging, expressing, sealing, and data transfer processes — providing efficient blood component production. The Blood Center now produces two types of platelets: apheresis and whole blood-derived, increasing overall availability and flexibility.

“What surprised us most was how quickly our team saw the value — not just in time saved, but in how much more confident we feel about the consistency of every unit,” said Wilson-Martin. “This is mission-critical, as the more efficient we are, the more lives we can save. We can get more blood and more consistent platelets to the hospitals and patients in our communities who depend on us.”

Gary Higgins, Vice President of Administrative Services at The Blood Center, emphasized the importance of consistency from a legal and operational standpoint. A former litigation lawyer, he attributes the consistently high product quality to greater peace of mind.

“Coming from a background in litigation, I’m trained to ask: ‘What’s the worst that can happen, and how do we prevent it?'” said Higgins. “Before Reveos, ensuring every unit met regulatory standards required more manual oversight and effort. Now, we have greater peace of mind. It’s reassuring to know that we’re delivering a product that meets all federal and state requirements, every time.”

Early wins and operational impact

Since implementing Reveos, The Blood Center has already seen measurable improvements, including increased platelet inventory — with up to 100 pooled platelet products manufactured per month — increasing availability for the more than 50 hospitals they serve.*

Other areas seeing improvement:

  • Reduced hands-on time, allowing staff to focus on other critical tasks and projects
  • Improved product consistency, resulting in a more reliable platelet supply with equivalent therapeutic doses
  • Reduced platelet waste due to lower expiration rates with a seven-day platelet shelf life

“It’s not just faster — it’s more predictable,” noted Wilson-Martin. “You gain control over your workflow, which is critical in a field where every drop counts.”

Impact beyond the lab

The benefits of Reveos extend beyond The Blood Center to hospitals and patients across Louisiana. Faster, more efficient processing means a more agile response to routine and emergency needs.

“With Reveos, we’re better prepared to meet the needs of our healthcare partners,” said Wilson-Martin. “We can breathe a little easier now, since we’re no longer worrying about what tomorrow will look like or whether we’ll have the platelets we need. It’s a meaningful step forward in strengthening the blood supply infrastructure for our communities.”

Looking ahead

This announcement is part of a broader movement toward whole blood automation in the U.S. Terumo BCT and The Blood Center will share insights from this transition in a joint abstract at the 2025 Association for the Advancement of Blood and Biotherapies (AABB) Annual Meeting in San Diego, where Billy Weales, President and CEO of The Blood Center, will speak at Terumo BCT’s Science and Innovation Theater session on Monday, October 27, between 11:45 a.m. and 12:45 p.m. PT.

*Data provided by The Blood Center.

[1].     American Red Cross. Red Cross declares emergency blood shortage, calls for donations during National Blood Donor Month. January 7, 2024. https://www.redcross.org/about-us/news-and-events/press-release/2024/red-cross-declares-emergency-blood-shortage-calls-for-donations-during-national-blood-donor-month.html

[2].     AABB. AABB24: What new data says about the state of the blood supply. October 21, 2024. https://www.aabb.org/news-resources/news/article/2024/10/21/aabb24–what-new-data-says-about-the-state-of-the-blood-supply

[3].     U.S. Department of Health and Human Services, Office of Infectious Disease and HIV/AIDS Policy. (2023). National Blood Collection and Utilization Survey. Updated January 9, 2024. Accessed October 13, 2025. https://www.hhs.gov/oidp/topics/blood-tissue-safety/surveys/national-blood-collection-and-utilization-survey/index.html

[4].     The Blood Center. About us. Accessed October 13, 2025. https://www.thebloodcenter.org/about-us

 

About the Reveos Automated Blood Processing System

Whole blood units are collected from donors and have traditionally been separated into components — platelets, plasma and red blood cells — using manual methods that took up to 26 steps. Reveos simplifies this process and eliminates over half of the steps. The system aims to help blood centers manage staffing and improve overall efficiency by obtaining more blood products from the same number of donors. It has been used around the world for more than a decade. Reveos is expected to help U.S. blood centers meet the growing demand for platelets, which control bleeding and are used to treat patients facing trauma, cancer and other chronic conditions.

Up to four units of whole blood are loaded into Reveos. The rotor spins, and the whole blood is separated into components. Plasma, platelets and red blood cells are expressed into their respective product bags, and each bag is sealed. After the procedure, the data is recorded using Terumo BCT’s Lumia Software Platform, which connects with Reveos to help blood centers and processing labs achieve operational targets.

Availability varies by region and country. Reveos is either a registered trademark or a trademark of Terumo BCT, Inc. in the United States and/or other countries. See TerumoBCT.com/Trademarks for details.

About The Blood Center

Founded in 1960, The Blood Center is the primary supplier of blood, blood components, and plasma derivatives to local hospitals throughout South Louisiana and parts of the Mississippi Gulf Coast. The Blood Center is a non-profit, community service organization guided by a volunteer Board of Directors, comprised of community leaders and hospital representatives.

The Blood Center’s mission is to provide a quality supply of blood components to meet the needs of the communities it serves, and to provide the technical support needed by the blood banking profession to achieve the highest safety and ethical standards.

The Blood Center supplies over 50 hospitals and numerous outpatient transfusion facilities in Southeast Louisiana and Southern Mississippi. Many of these hospitals, including Children’s Hospital in New Orleans, University Medical Center (Level I Trauma Center) and St. Tammany Parish Hospital, treat patients from throughout this region. 

About Terumo BCT

Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees worldwide believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.

Terumo Blood and Cell Technologies’ customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 160 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.

We have global headquarters in Lakewood, Colorado, U.S.A., along with five regional headquarters, eight manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.

 

Media Contacts 

Terumo Blood and Cell Technologies  
Nicole Dobkin 
+1.720.763.5308 
Nicole.Dobkin@TerumoBCT.com   
Press@TerumoBCT.com   

Image Box Communications 
Michelle Boxall 
+44(0)20.8943.4685 
Michelle@IBcomms.agency     

 

 

Invitation to Electrolux Group Capital Markets Update, December 4, 2025

STOCKHOLM, Oct. 22, 2025 /PRNewswire/ — Electrolux Group has the pleasure of inviting investors, financial analysts and business media representatives to its Capital Markets Update on December 4, 2025.

The Capital Markets Update (CMU) will be held at Electrolux Group headquarters on S:t Göransgatan 143 in Stockholm, Sweden, starting at 14.00 CET on December 4, 2025, with registration from 13.30 CET. A live webcast will also be available.

The agenda will include presentations by Yannick Fierling, President and CEO, and members of the Group Management team between 14.00 CET and approx. 15.30 CET. The CMU provides an opportunity for participants to get an update on Electrolux Group strategy and priorities ahead. Presentations and Q&A sessions will be followed by a brand experience tour. Please note that only presentations and Q&A sessions will be webcasted live. The CMU is planned to end at approx. 17.30 CET.

Click HERE to register for the event in-person at the Electrolux Group headquarters.

Click HERE to join the webcast event online.

Register your participation for the event in-person no later than November 20. Please note that the number of participants attending in person is limited. More information, including the full agenda, will be made available on the registration sites further ahead.

For more information, contact:
Ann-Sofi Jönsson, Head of Investor Relations & Sustainability Reporting, phone +46 73 025 10 05,
ann-sofi.jonsson@electrolux.com

Henry Sjölin, Investor Relations Manager, phone +46 76 863 51 85, henry.sjolin@electrolux.com

Maria Åkerhielm, Investor Relations Manager, phone +46 70 796 38 56, maria.akerhielm@electrolux.com

Media: Electrolux Group Press Hotline, phone +46 8 657 65 07

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/electrolux-group/r/invitation-to-electrolux-group-capital-markets-update–december-4–2025,c4254705

The following files are available for download:

https://mb.cision.com/Main/1853/4254705/3738102.pdf

Invitiation to Electrolux Capital Markets Update Dec 4

 

/C O R R E C T I O N — Chery International/

In the news release, 2025 Chery International User Summit: Shaping the Industry’s Future Through Co-Creation and Innovation, issued 21-Oct-2025 by Chery International over PR Newswire, we are advised by the company that the release contained inaccuracies in the description of the “Chery Global ESG Advisory Alliance”. The complete, corrected release follows:

2025 Chery International User Summit: Shaping the Industry’s Future Through Co-Creation and Innovation

WUHU, China, Oct. 21, 2025 /PRNewswire/ — On October 21, 2025, the 2025 Chery International User summit — a global gathering transcending geography and culture — was grandly held in Wuhu, China.

With the theme “Co-Create, Co-Define,” the event brought together more than 3,000 participants from nearly 100 countries, including overseas users, dealership partners, members of the ESG Advisory Alliance, and international media representatives, to engage in an in-depth dialogue about the future of mobility.

2025 Chery International User summit
2025 Chery International User summit

In his keynote address at the opening ceremony, Yin Tongyue, Chairman of Chery Automobile Co., Ltd. (9973.HK), elaborated on the strategic essence of “Co-Create, Co-Define.”

From January to September 2025, Chery Group’s global sales surpassed 2 million units, with European sales more than doubling year-on-year to reach 145,000 units, showcasing the tangible value of global co-creation.

Mr. Yin emphasized that Chery is evolving from an automobile manufacturer into a builder of intelligent mobility ecosystems. Guided by the principle “In somewhere, For somewhere, Be somewhere,” the Group continues to advance localization by partnering with local universities and enterprises to develop localized products and nurture local talent, striving to become a truly local enterprise.

He also emphasized that ESG is central to sustainable development. Chery will continue working with international organizations to advance low-carbon technologies and public welfare initiatives, fulfilling its responsibility as a global corporate citizen. Mr. Yin concluded by reaffirming Chery Group’s commitment to building an open, inclusive, and sustainable automotive ecosystem together with its global partners.

Speech from Yin Tongyue, Chairman of Chery Automobile Co., Ltd. (9973.HK)
Speech from Yin Tongyue, Chairman of Chery Automobile Co., Ltd. (9973.HK)

Co-Creation — Building an Open and Collaborative User Ecosystem

Global Voices, Shared Stories

At the User Awards Ceremony, representatives from Vietnam, South Africa, Kazakhstan, Spain, and Indonesia shared their stories of connection with Chery.

Le Nguyen Bao Ngoc, brand ambassador for OMODA & JAECOO Vietnam, integrates sustainability into brand communication. Samurai Farai, a South African artist, infused local culture into Chery through creative vehicle art. Mussa Ramazanov from Kazakhstan demonstrated the reliability of EXEED vehicles after driving over 100,000 km. Carlos Guisado from Spain and his family showcased their deep trust by choosing the OMODA & JAECOO brand. Humam from Indonesia built a local community of over 300 Chery owners, forming a thriving content ecosystem.

From CHERY, OMODA & JAECOO, and EXEED to iCAUR, LEPAS, and LUXEED, users around the world are not just customers — they are co-creators shaping Chery’s global brand narrative. Their authentic engagement gives Chery a warmer, more human presence in the global marketplace.

Users awards Ceremony
Users awards Ceremony

Expanding the ESG Alliance: Building a Global Network for Sustainability

A key highlight of the conference was the launch of the Chery Global ESG Advisory Alliance, marking a major upgrade in Chery’s sustainability strategy.

This year, the alliance expanded significantly — welcoming experts from global sustainability organizations and industrial chain partners.

Notably, former UN Secretary-General Ban Ki-moon attended in person and officially joined the alliance as an ESG Honorary Advisor.

His participation not only enhanced the alliance’s international credibility but also reflected global recognition of Chery’s sustainability roadmap. Through this upgraded alliance, Chery is transforming ESG from an internal corporate initiative into a global collaborative movement, promoting deep cooperation in low-carbon R&D, public welfare programs, and industry standardization.

Launching ceremony of Chery Global ESG Advisory Alliance
Launching ceremony of Chery Global ESG Advisory Alliance

At the ESG strategy level, Chery has built a comprehensive framework supported by three key pillars: “Low-Carbon Transition and Nature Positive,” “Value Chain Collaboration,” and “Self-Discipline and Compliance Development.” The Group has already made substantial progress across multiple dimensions.

On the technological front, Chery promotes low-carbon transformation through innovations such as the Mars Architecture Hybrid Platform and solid-state battery technology.

On the environmental front, it became the first Chinese automaker to receive a mutual recognition report for Life Cycle Assessment (LCA) between China and the EU.

On the social responsibility front, Chery continues to collaborate with UNICEF on the “Empowering Every Child’s Learning Journey” initiative and works with the IUCN to advance global nature conservation projects — demonstrating its firm commitment to turning ESG promises into tangible action.

Co-Define — Shaping the Strategic Blueprint for Intelligent Mobility

Strategic Elevation Defines a New Paradigm for Intelligent Mobility 

In the grand finale, Mr. Zhang Guibing, President of Chery International, delivered a keynote speech themed “Co-Creating Sustainable Development, Co-Defining the Future Ecosystem,” elaborating on Chery’s strategic evolution from a traditional automaker to a builder of intelligent mobility ecosystems.

He noted that Chery has ranked No.1 among Chinese brands in overseas sales for 22 consecutive years, with monthly exports exceeding 100,000 units for five consecutive months. Its new energy vehicle growth rate leads among China’s top five auto brands, and PHEV models have achieved No.1 retail sales in multiple markets — achievements that firmly validate the foundation of Chery’s strategic transformation.

Driven by the global trends of low-carbon transition and AI intelligence, the automotive industry is rapidly evolving toward an integrated “vehicle + ecosystem” model. In this context, Chery is building a comprehensive technology ecosystem that transcends the traditional automotive domain — one that deeply integrates users, vehicles, robots, and big data.

This system is anchored in intelligent, connected new energy vehicles, while extending into emerging fields such as flying cars, robotaxis, robotics, photovoltaics, and green energy, forming a diversified and synergistic innovation network. Moving forward, Chery will dedicate part of its teams to the automotive business and others to the research, development, and operation of new ventures like robotics, jointly shaping a future-oriented mobility ecosystem.

Mr. Zhang further detailed Chery’s roadmap: Strengthening leadership in PHEV hybrid and BEV electric platforms. Accelerating commercialization of autonomous driving technologies. Advancing innovation in robotics and aerial mobility. Deepening localization under the philosophy “In somewhere, For somewhere, Be somewhere.”

This strategic transformation marks Chery’s evolution from a traditional automaker into a green, intelligent mobility technology company that co-creates, co-defines, and co-prospers with its users and partners. By building an open and collaborative innovation ecosystem, Chery is not only redefining the boundaries of the mobility industry but also opening new pathways for shared growth with global partners.

Speech from Mr. Zhang Guibing, President of Chery International
Speech from Mr. Zhang Guibing, President of Chery International

Co-Create. Co-Define. Co-Win the Future.

Through its dynamic structure of speeches, dialogues, and collaborative announcements, the 2025 Chery International User Summit vividly embodied its theme of “Co-Create, Co-Define.”

From Ban Ki-moon’s participation to user stories from across the globe, from the robotic performances that opened the event to the upgraded ESG Alliance, Chery conveyed a clear message to the world:
It is not building a closed product system, but an open, evolving, user-driven mobility ecosystem.

As technology converges with humanity, and users evolve from product consumers to ecosystem co-creators, Chery’s vision extends beyond cars — toward a new way for people to connect with the world.